Differential pattern of response in mood symptoms and suicide risk measures in severely ill depressed patients assigned to citalopram with placebo or citalopram combined with lithium: Role of lithium levels

Journal of Psychiatric Research

Volumn 45, Issue 11, 2011, Pages 1489-1496

  Khan, Arif ^a,b,c   Khan, Shirin R F ^a,c   Hobus, Joy ^a,c   Faucett, James ^a   Mehra, Vishaal ^d   Giller, Earl L ^e   Rudolph, Richard L ^a  

^a Northwest Clinical Research Center   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Columbia Northwest Pharmaceuticals ^*  (United States)

^d Artemis Institute for Clinical Research   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Citalopram; Clinical trial design; Depression; Lithium; Suicidality; Suicide

Indexed keywords

CITALOPRAM; LITHIUM CARBONATE; PLACEBO;

ADULT; ANXIETY; APPETITE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD CHANGE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 80053972290     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2011.06.016     Document Type: Article

References (31)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2000, Washington, D.C.
2. Baldessarini R.J., Tondo L., Hennen J. Treating the suicidal patient with bipolar disorder. Reducing suicide risk with lithium. Annals of the New York Academy of Sciences 2001, 932:24-38.
3. Baldessarini R.J., Tondo L., Hennen J. Lithium treatment and suicide risk in major affective disorders: update and new findings. The Journal of Clinical Psychiatry 2003, 64(Suppl. 5):44-52.
4. Beck A.T., Steer R.A. Manual for Beck hopelessness scale 1988, Psychological Corporation, San Antonio, TX.
5. Beck A.T., Steer R.A. Manual for Beck scale for suicide ideation 1991, Psychological Corporation, San Antonio, TX.
6. Boekholdt S.M., Peters R.J. Rimonabant: obituary for a wonder drug. Lancet 2010, 376:489-490.
7. Cipriani A., Pretty H., Hawton K., Geddes J.R. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. The American Journal of Psychiatry 2005, 162:1805-1819.
8. Coric V., Stock E.G., Pultz J., Marcus R., Sheehan D.V. Sheehan suicidality tracking scale (Sheehan-STS): preliminary results from a multicenter clinical trial in generalized anxiety disorder. Psychiatry (Edgmont) 2009, 6:26-31.
9. DiazGranados N., Ibrahim L.A., Brutsche N.E., Ameli R., Henter I.D., Luckenbaugh D.A., et al. Rapid resolution of suicidal ideation after a single infusion of an N-Methyl-D-Aspartate agonist in patients with treatment-resistant major depressive disorder. The Journal of Clinical Psychiatry 2010, 71:1605-1611.
10. Guy W. ECDUE assessment manual for psychopharmacology 1976, US Department of Health, Education and Welfare, Reocville, MD.
11. Guzzetta F., Tondo L., Centorrino F., Baldessarini R.J. Lithium treatment reduces suicide risk in recurrent major depressive disorder. The Journal of Clinical Psychiatry 2007, 68:380-383.
12. Haahr M. Random.org. 2011 2011, Retrieved from:. http://www.random.org/.
13. Kapusta N.D., Mossaheb N., Etzersdorfer E., Hlavin G., Thau K., Willeit M., et al. Lithium in drinking water and suicide mortality. The British Journal of Psychiatry 2011, 198:346-350.
14. Khan A., Khan S.R., Leventhal R.M., Brown W.A. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration database. International Journal of Neuropsychopharmacology 2001, 4:113-118.
15. Khan A., Schwartz K. Suicide risk and symptom reduction in patients assigned to placebo in duloxetine and escitalopram clinical trials: analysis of the FDA summary basis of approval reports. Annals of Clinical Psychiatry 2007, 19:31-36.
16. Khan A., Warner H.A., Brown W.A. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Archives of General Psychiatry 2000, 57:311-317.
17. Lauterbach E., Felber W., Muller-Oerlinghausen B., Ahrens B., Bronisch T., Meyer T., et al. Adjunctive lithium treatment in the prevention of suicidal behaviour in depressive disorders: a randomised, placebo-controlled, 1-year trial. Acta Psychiatrica Scandinavica 2008, 118:469-479.
18. Linehan M.M. Suicide intervention research: a field in desperate need of development. Suicide and Life-Threatening Behavior 2008, 38:483-485.
19. Linehan M.M., Comtois K.A., Murray A.M., Brown M.Z., Gallop R.J., Heard H.L., et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry 2006, 63:757-766.
20. Mann J.J., Apter A., Bertolote J., Beautrais A., Currier D., Haas A., et al. Suicide prevention strategies: a systematic review. JAMA 2005, 294:2064-2074.
21. Meltzer H.Y., Alphs L., Green A.I., Altamura A.C., Anand R., Bertoldi A., et al. Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (InterSePT). Archives of General Psychiatry 2003, 60:82-91.
22. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. The British Journal of Psychiatry 1979, 134:382-389.
23. Ohgami H., Terao T., Shiotsuki I., Ishii N., Iwata N. Lithium levels in drinking water and risk of suicide. The British Journal of Psychiatry 2009, 194:464-465. discussion 446.
24. Patorno E., Bohn R.L., Wahl P.M., Avorn J., Patrick A.R., Liu J., et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA 2010, 303:1401-1409.
25. Posner K.D., Lucas C., Gould M., Stanley B., Fisher P., Zelezny J., et al. Columbia-suicide severity rating scale 2007, New York.
26. Schrauzer G.N., Shrestha K.P. Lithium in drinking water and the incidences of crimes, suicides, and arrests related to drug addictions. Biological Trace Element Research 1990, 25:105-113.
27. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. The Journal of Clinical Psychiatry 1998, 59(Suppl. 20):22-33. quiz 34-57.
28. Thompson Reuters Physicians' desk reference 2009, Thompson Reuters, Montvale. 63rd ed.
29. United States Food and Drug Administration FDA requires warnings about risk of suicidal thoughts and behavior for antiepileptic medications 2008, Retrieved from:. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116991.htm.
30. United States Food and Drug Administration FDA requires new boxed warnings for the smoking cessation drugs chantix and zyban 2009, Retrieved from:. http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm170906.htm.
31. Zimmerman M., Mattia J.I., Posternak M.A. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?. The American Journal of Psychiatry 2002, 159:469-473.